Sentences with phrase «develop small molecule inhibitors»

Our strategy is to identify basic mechanisms of proteins involved in metabolism and DNA repair to gain better understanding in disease and also develop small molecule inhibitors to selectively targeting these proteins as potential therapeutics.

Vescor, advised by its scientific founders White and Kimmelman, whose research has shown inhibition of autophagy can dramatically impact tumor growth in pre-clinical models, will develop small molecule inhibitors of a number of protein targets at critical nodes of the autophagy cascade, perform investigational new drug (IND) enabling studies, and move these into clinical development.

turned into 10 years of systematic research to identify the enzyme PLK4 as a promising therapeutic target and develop a small molecule inhibitor to block it,» says Dr. Mak, Director of The Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, University Health Network.

Not exact matches

Our team is currently developing methods that can be used to screen small molecule inhibitors of EDD1 and also looking into how the regulation of TIP60 levels can be translated into therapeutic advances for the treatment of viral - mediated cancers such as cervical cancer.

Hu and his collaborator Juan R. Del Valle at the University of South Florida are developing novel small molecule inhibitors against IRE - 1 to combat cancers associated with high numbers of MDSCs.

iTeos is now developing EOS200271 which is a synthetic, small molecule inhibitor of indoleamine 2,3 - dioxygenase (IDO1), which has demonstrated the same anti-tumour activity in multiple preclinical tumour models in combination with immune checkpoint inhibitors as competitors, but also has demonstrated superior brain penetration.

Navire Pharma is a new company aimed at developing novel small - molecule inhibitors of a tyrosine - protein phosphatase called SHP2 (also known as PTPN11) for genetically - driven and treatment - resistant cancer.

Bae N, Viviano M, Su X, Lv J, Cheng D, Sagum C, Castellano S, Bai X, Johnson C, Khalil MI, Shen J, Chen K, Li H, Sbardella G, Bedford MT. (2017) Developing Spindlin1 small - molecule inhibitors by using protein microarrays.

The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company aimed at developing novel small - molecule inhibitors of a tyrosine - protein phosphatase called SHP2 for genetically driven and treatment - resistant cancer.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

His thesis work focused on developing novel small molecule inhibitors against protein targets such as survivin and STAT3 that are essential for progression and survival of cancer.

In fact, Liu notes that pharmaceutical companies are trying to develop small molecule HIF inhibitors as cancer treatment.

The lab further developed inhibitors to target the expression of XBP - 1 and established that blocking the expression of XBP - 1 by specific small - molecule chemical inhibitors can stall malignant progression of leukemia in mice and induce apoptosis in primary human leukemic cells.